J Liver Cancer.  2016 Mar;16(1):1-6. 10.17998/jlc.2016.16.1.1.

Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma

Affiliations
  • 1Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. baesh@catholic.ac.kr

Abstract

Sorafenib is the standard treatment for advanced hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging system. However, because of its unsatisfactory efficacy, adverse effects, and high cost, the use of sorafenib is limited, and other treatment modalities are required. Recent studies reported that treatment modalities other than sorafenib, such as hepatic arterial infusion chemotherapy and transarterial radioembolization, showed comparable or better response rates and survival rates than sorafenib. In this review, treatment modalities that could be used as alternatives to sorafenib will be discussed.

Keyword

Hepatocellular carcinoma; Sorafenib; Hepatic arterial infusion chemotherapy; Radioembolization
Full Text Links
  • JLC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr